ACE2 News and Research

RSS

Compelling study shows heparin may protect against COVID-19

A compelling new study conducted by an international team of researchers has demonstrated that the widely used blood-thinning medication - heparin - can block infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

16 Jul 2020

Prominent pharmacologist calls for new approach to treat COVID-19

A prominent Australian pharmacologist has called for a new approach to treating COVID-19 as hopes fade of finding an effective vaccine or antiviral before the end of the year.

16 Jul 2020

Selective statins may reduce SARS-CoV-2 cell entry and inhibit infection

Statins are a class of drugs often used to control high cholesterol levels in obesity. Now, a study published on the preprint server medRxiv* in July 2020 suggests that statins do not aggravate the risk of COVID-19 infection and may have a small beneficial effect in some cases.

16 Jul 2020

Children with MIS-C have different antibody responses than adults with COVID-19

A new study published on the preprint medRxiv in July 2020 reveals that children with the condition Multisystem Inflammatory Syndrome in Children (MIS-C) have a distinctly different pattern of antibody generation compared to adults with COVID-19 disease.

16 Jul 2020

Study explains why fetuses and newborns are mostly spared by COVID-19

Amid the coronavirus pandemic, it has been previously suggested that the most vulnerable individuals to developing severe coronavirus disease (COVID-19) include the elderly, those with underlying health conditions, and those who have weakened immune systems.

15 Jul 2020

Study provides new insights into genetic susceptibility of COVID-19

A new Cleveland Clinic study has identified genetic factors that may influence susceptibility to COVID-19. Published today in BMC Medicine, the study findings could guide personalized treatment for COVID-19.

15 Jul 2020

Obesity and metabolic syndrome increase risk for severe influenza, COVID-19

Metabolic syndrome increases the risk of severe disease from viral infection, according to a review of the literature performed by a team of researchers from St. Jude Graduate School of Biomedical Sciences and the University of Tennessee Health Science Center, both in Memphis.

15 Jul 2020

Common FDA-approved drug may be a powerful tool in fighting COVID-19

A common drug, already approved by the Food and Drug Administration, may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.

15 Jul 2020

Study: Amount of SARS-Cov-2 receptor is increased in patients with pre-existing cardiac conditions

Nearly 20% of all COVID-19-associated deaths are from cardiac complications, yet the mechanisms from which these complications arise have remained a topic of debate in the cardiology community.

15 Jul 2020

Mobility and flexibility in SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in July 2020 describes the use of in silico modeling of potential drug targets on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein structures, using data retrieved from the Protein Databank (PDB).

15 Jul 2020

Strong evidence several FDA approved drugs block SARS-CoV-2 in relevant cell-lines and human organoids

Now, a new study describes how compounds that restore the normal transcriptional conditions following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be used to reduce viral load without neutralizing the virus entry into the host cell.

15 Jul 2020

Llama nanobodies block SARS-CoV-2 infection in vitro

Now, a team of scientists at the United Kingdom's Rosalind Franklin Institute may have a surprising solution for the coronavirus pandemic, which has killed more than 574,000 people worldwide.

14 Jul 2020

Cold sensitivity of SARS-CoV-2 could impact vaccine studies

Researchers at Duke University in Durham, USA, have made an important discovery about the spike protein on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could have a broad impact on vaccine studies.

14 Jul 2020

Investigational antidepressant PT150 shows antiviral activity against SARS-CoV-2

In a recent bioRxiv study, an ad hoc multi-institutional research team from the US shows that a novel hormone receptor modulator PT150 has unique and possibly additive antiviral and immunomodulatory effects – highlighting its potential role in the treatment and prophylaxis of coronavirus disease (COVID-19).

14 Jul 2020

Tobacco smoking and vaping nicotine may exacerbate COVID-19 inflammation

Researchers in San Diego have conducted a study showing that both smoking and the use of e-cigarettes containing nicotine and flavorings may critically exacerbate inflammation in cases of coronavirus disease 2019 (COVID-19) and significantly worsen clinical outcomes.

14 Jul 2020

Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

From Absolute Antibody Ltd 14 Jul 2020

UTHealth physicians investigate blood pressure drug's effect on improving COVID-19 outcomes

An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston.

14 Jul 2020

Researchers stabilize the closed SARS-CoV-2 spike trimer

Now, a new study by researchers at Janssen Vaccines & Prevention BV and Leiden University and published on the preprint server bioRxiv uses cryoEM to reveal the structure of this trimer, in order to support both vaccine development and diagnostic testing based on antibody production.

14 Jul 2020

COVID-19 – researchers sum up the “Tsunami” of information

The severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection leading to COVID-19 is a raging pandemic across the world at present. It has infected 13 million and killed 571,000 individuals around the world as of today. The infection was first reported in Wuhan, Hubei Province of China in late December 2019.

13 Jul 2020

Serology distinguishes children with MIS-C associated with COVID-19

Researchers in the United States say that measuring antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may help to distinguish between multisystem inflammatory syndrome in children (MIS-C) and other clinically similar syndromes.

13 Jul 2020